Free Trial
→ Today's free pick (on me) (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$19.72
-2.1%		$24.69
$4.97
▼
$45.50
$143.17M2.79334,118 shs96,319 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,426 shs479 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
+7.53%+3.71%-27.19%-28.68%-96.81%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%0.00%-20.00%-20.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$19.72
-2.1%		$24.69
$4.97
▼
$45.50
$143.17M2.79334,118 shs96,319 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,426 shs479 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
+7.53%+3.71%-27.19%-28.68%-96.81%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%0.00%-20.00%-20.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
2.33
Hold$83.00319.40% Upside
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CUE and SYRS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold
9/18/2026
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$83.00
9/18/2026
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$83.00
9/17/2026
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
8/27/2026
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/13/2026
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
(Data available from 11/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$27.47M5.23N/AN/A$10.08 per share1.96
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.03N/AN/A$0.79 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$26.60M-$27.02N/AN/AN/A-435.83%-620.06%-291.15%11/11/2026 (Estimated)
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%N/A

Latest CUE and SYRS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026Q3 2026
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$2.2433N/AN/AN/A$1.03 millionN/A
8/14/2026Q2 2026
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$1.69-$24.14-$22.45-$24.14$3.00 million$7.88 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/A
1.25
1.25
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25

Institutional Ownership

CompanyInstitutional Ownership
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
35.04%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%

Insider Ownership

CompanyInsider Ownership
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
14.56%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
297.26 million6.21 millionNo Data
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
6826.83 million23.54 millionNo Data

Recent News About These Companies

Syros Pharmaceuticals stock remains tied to Nasdaq delisting process
October 30, 2026  |  ad-hoc-news.deA
Syros approves wind-down: what it means for Syros Pharmaceuticals stock
October 6, 2026  |  ad-hoc-news.deA
Syros Pharmaceuticals stock trades at USD 0.0004 after delisting
October 4, 2026  |  ad-hoc-news.deA
SYRS stock reflects a 2025 Nasdaq delisting and wind down
September 30, 2026  |  ad-hoc-news.deA
Syros Pharmaceuticals stock holds steady as market data reset
September 23, 2026  |  ad-hoc-news.deA
Syros Announces Pricing of $75.6 Million Public Offering of Common Stock
July 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20210119006194/en/Syros-Announces-Pricing-of-%2475.6-Million-Public-Offering-of-Common-Stock
Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals
April 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/rege-nephro-buys-tamibarotene-related-assets-from-syros-pharmaceuticals/ar-AA1CX7u7
Syros Pharmaceuticals trading resumes
March 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/syros-pharmaceuticals-trading-resumes-1034427505
Syros Pharmaceuticals Plans to Wind Down Operations
March 1, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/syros-pharmaceuticals-plans-to-wind-down-operations-948b139e
Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock
March 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/syros-pharmaceuticals-voluntarily-delists-from-nasdaq-deregisters-common-stock-1034427422
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
February 28, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250228459350/en/syros-announces-voluntary-delisting-from-nasdaq-and-sec-deregistration/
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline
January 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/syros-pharmaceuticals-stock-hits-52-week-low-at-0-18-amid-steep-decline/ar-AA1y4cfB
Syros Pharmaceuticals Inc (SYRS) Stock Price Reaches $0.22: What Factors Are Influencing This Level?
January 18, 2025  |  bovnews.comB
What’s Causing Syros Pharmaceuticals Inc (SYRS) Stock’s -96.35% Drop Over the Last Six Months?
January 16, 2025  |  bovnews.comB
SYRS’s Latest Surge: What’s Behind the Spike?
January 6, 2025  |  bovnews.comB
The SYRS Conundrum: Why Syros Pharmaceuticals Inc’s Stock Is Making Headlines Again
January 2, 2025  |  bovnews.comB
Analysts Predict a $15 Target for Syros Pharmaceuticals Inc (SYRS) Stock—What Could Drive It There?
December 31, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock: More Resilient Than It Appears
December 27, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock Dive: The Hidden Causes Revealed
December 26, 2024  |  bovnews.comB
What’s Fueling Syros Pharmaceuticals Inc (SYRS) Stock’s -94.59% Loss Below Its 200-Day SMA?
December 14, 2024  |  bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cue Biopharma stock logo

Cue Biopharma NASDAQ:CUE

$19.72 -0.42 (-2.09%)
As of 02:17 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0004 0.00 (0.00%)
As of 10:31 AM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas